Medicenna Therapeutics' Unattributed Round

Medicenna Therapeutics raised a round of funding on December 01, 2016.

Medicenna is a clinical stage, privately held, immuno-oncology company developing first-in-class, Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R)…

Articles about Medicenna Therapeutics' Unattributed Round: